Investors recently learned about undisclosed data from one of Amgen's clinical trials. The new information didn't look favorable at first glance. During clinical trials, especially those in phase 1 safety testing, investigators are obligated to capture a ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.

Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% weight on average in a year-long mid-stage trial, although its shares tumbled 12% on Tuesday after the data failed to meet lofty investor expectations.

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in those with diabetes after a year in a phase 2 trial. Despite higher discontinuation rates compared to other drugs,